Zacks Research Analysts Decrease Earnings Estimates for BMY

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at Zacks Research lowered their Q3 2025 earnings estimates for shares of Bristol Myers Squibb in a report issued on Tuesday, October 21st. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $1.33 for the quarter, down from their previous forecast of $1.62. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2026 earnings at $5.89 EPS, Q3 2027 earnings at $1.43 EPS and FY2027 earnings at $5.78 EPS.

Several other analysts also recently weighed in on BMY. Weiss Ratings reiterated a “hold (c-)” rating on shares of Bristol Myers Squibb in a research report on Tuesday, October 14th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Daiwa Capital Markets downgraded shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a research report on Tuesday, August 5th. Finally, Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $57.23.

Bristol Myers Squibb Trading Down 0.4%

Shares of NYSE:BMY opened at $44.36 on Thursday. The company has a market cap of $90.29 billion, a PE ratio of 17.89, a P/E/G ratio of 2.32 and a beta of 0.33. The company’s 50-day moving average price is $45.92 and its 200 day moving average price is $47.28. Bristol Myers Squibb has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. Bristol Myers Squibb’s quarterly revenue was up .6% compared to the same quarter last year. During the same period last year, the firm posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.6%. The ex-dividend date is Friday, October 3rd. Bristol Myers Squibb’s payout ratio is presently 100.00%.

Insider Activity at Bristol Myers Squibb

In related news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares in the company, valued at $7,922,048.07. The trade was a 25.07% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by insiders.

Institutional Trading of Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Cerity Partners LLC raised its holdings in shares of Bristol Myers Squibb by 9.2% in the 3rd quarter. Cerity Partners LLC now owns 942,270 shares of the biopharmaceutical company’s stock worth $42,496,000 after purchasing an additional 79,647 shares in the last quarter. Tilson Financial Group Inc. raised its holdings in shares of Bristol Myers Squibb by 4.2% in the 3rd quarter. Tilson Financial Group Inc. now owns 6,445 shares of the biopharmaceutical company’s stock worth $291,000 after purchasing an additional 259 shares in the last quarter. Mccarter Private Wealth Services LLC raised its holdings in shares of Bristol Myers Squibb by 5.0% in the 3rd quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock worth $222,000 after purchasing an additional 235 shares in the last quarter. CoreCap Advisors LLC increased its position in shares of Bristol Myers Squibb by 14.8% in the third quarter. CoreCap Advisors LLC now owns 20,309 shares of the biopharmaceutical company’s stock worth $916,000 after acquiring an additional 2,613 shares in the last quarter. Finally, Abundance Wealth Counselors increased its position in shares of Bristol Myers Squibb by 5.3% in the third quarter. Abundance Wealth Counselors now owns 38,328 shares of the biopharmaceutical company’s stock worth $1,729,000 after acquiring an additional 1,929 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.